Clinical trials: Primary Headache Disorders
Migraine Headaches
To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches
to demonstrate the superiority of Trexima (combination of sumatriptan as the succinate 85 mg and naproxen sodium 500 mg) versus placebo in the acute treatment of migraine to demonstrate the superiority of Trexima versus the…
- Trial name
- NCT00434083
- Testing
- sumatriptan, naproxen sodium
- Where
- 2 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- POZEN
Headache
An Open-label Study to Evaluate Topiramate Therapy in Migraine Patients, and Its Effects on Subject Responsiveness to Migraine Treatment With Triptans
The purpose of this study is to evaluate whether prophylactic use of topiramate (preventative use before a migraine attack) enhances the effectiveness of migraine treatment with triptans.
- Trial name
- NCT00261469
- Testing
- topiramate
- Volunteers
- 38 people
- Sponsor
- Janssen-Ortho Inc., Canada
Migraine
Study on the Pharmacokinetics (PK) of DFN-15 vs Comparator and Food-effect on DFN-15 PK in Healthy Adult Subjects
An Open-Label, Three-Way Randomized, Single Dose Crossover Study Comparing Bioavailability of DFN-15 under fasting conditions versus Comparator under fed conditions and to determine food-effect of DFN-15 in Healthy Adult Subjects
- Trial name
- NCT03282838
- Testing
- DFN-15 (fasted), DFN-15 (fed), Comparator Celebrex® (fed)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Migraine, Photophobia
An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack
The purpose of the study is to show the efficacy of a single dose of PRO-513 for treating subjects suffering moderate pain form a migraine attack, with or without aura.
- Conditions
- Migraine, Photophobia, Phonophobia
- Trial name
- NCT00330850
- Testing
- PRO-513
- Where
- 16 sites in United States
- Volunteers
- 650 people
- Sponsor
- ProEthic Pharmaceuticals
Migraine
A Study of Prophylaxis for Migraine Patients With Topiramate in India
The purpose of this study is to evaluate the safety and effectiveness of topiramate in preventing migraine among Indian participants requiring prophylaxis (measure taken to maintain health and prevent the spread of disease).
- Trial name
- PROMPT-IN (NCT01836874)
- Testing
- No intervention
- Volunteers
- 209 people
- Sponsor
- Janssen-Cilag Ltd.
Migraine Disorders
Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)
Study KCC-SMT-002, is a Phase 1, single-site, open-label, non-randomized, crossover, flexible dose design study to investigate the pharmacokinetic (PK) and safety comparing the Sofusa™ system with sumatriptan (KC5010) to Imitrex®…
- Trial name
- KCC-SMT-002 (NCT03229798)
- Testing
- Sumatriptan Succinate Oral Tablet, Transdermal delivery of sumatriptan succinate
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Sorrento Therapeutics, Inc.
Migraine
The Effectiveness and Safety of Topiramate on Prevention of Chronic Migraine
The purpose of this study is to evaluate the safety and effectiveness of individualized doses (50 to 200 milligrams) of topiramate tablets compared against placebo for the prevention of chronic migraine headaches over a period of…
- Trial name
- NCT00216606
- Testing
- topiramate
- Volunteers
- 59 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Migraine
Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition
The purpose of this study is to evaluate the pharmacokinetics (PK) of BMS-927711 during migraine and non-migraine condition.
- Trial name
- NCT01445067
- Testing
- BMS-927711 (CGRP Antagonist)
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Pfizer
Migraine, Migraine Headache
Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine
The purpose of this migraine prevention study is to evaluate the efficacy and safety of AST-726 in moderate to severe migraine patients at one of two doses compared to placebo and compared to a baseline period as measured by a…
- Conditions
- Migraine, Migraine Headache, Migraine Disorders, Migraine With Aura
- Trial name
- NCT00285402
- Testing
- AST-726 Low dose, AST-726 High dose
- Where
- 19 sites in Finland, Netherlands and 1 more
- Volunteers
- 198 people
- Sponsor
- Ariston Pharmaceuticals, Inc.
Migraine
A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as Galcanezumab in Japanese participants with migraine.
- Trial name
- NCT02959190
- Testing
- Galcanezumab
- Where
- 44 sites in Japan
- Volunteers
- 311 people
- Sponsor
- Eli Lilly and Company
Migraine
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
A migraine attack is a moderate or severe headache that usually occurs on one side of the head and is often accompanied by throbbing, sensitivity to light, sensitivity to sound, nausea, or other symptoms.
- Trial name
- ATO ACUTE (NCT06241313)
- Testing
- Atogepant
- Where
- 149 sites in Belgium, China and 13 more
- Volunteers
- 2,158 people
- Sponsor
- AbbVie
Resistant Migraine, Chronic Migraine Headache
A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine
The purpose of this pivotal clinical study is to evaluate the safety and effectiveness of the MySalvia System, a minimally invasive implantable neuromodulation therapy, for the preventive treatment of adults with resistant…
- Conditions
- Resistant Migraine, Chronic Migraine Headache, Headache (Migraine), Headache, Cluster
- Trial name
- RECLAIM-II (NCT07719608)
- Testing
- Neurostimulator
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Salvia BioElectronics
Migraine
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
The purpose of this study is to see how safe and effective Lacosamide (LCM) is when taken by mouth, twice a day for up to 18 weeks to prevent migraines.
- Trial name
- SP906 (NCT00440518)
- Testing
- Lacosamide
- Where
- 24 sites in United States
- Volunteers
- 218 people
- Sponsor
- UCB Pharma
Migraine Disorders
Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment
The purpose of this study is to evaluate the efficacy and safety of a range of oral doses of COL-144 in treating migraine headache, in order to select a dose or doses for further evaluation.
- Trial name
- NCT00883051
- Testing
- Lasmiditan
- Where
- 39 sites in Belgium, Finland and 3 more
- Volunteers
- 512 people
- Sponsor
- Eli Lilly and Company
Chronic Cluster Headache
Pathway CH-1 Long-Term Follow-Up
The objective of the study is to demonstrate the long-term safety and performance of the ATI Neurostimulation System when used for stimulation of the sphenopalatine ganglion (SPG) in cluster headache subjects.
- Trial name
- NCT01616511
- Where
- 3 sites in Belgium, Denmark and 1 more
- Volunteers
- 33 people
- Sponsor
- Autonomic Technologies, Inc.
Migraine Headache
Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)
A study to compare rizatriptan 10 mg verse sumatriptan 100 mg in the treatment of migraine attacks and duration of relief provided.
- Trial name
- NCT00898677
- Testing
- rizatriptan benzoate, Comparator: sumatriptan
- Volunteers
- 1,268 people
- Sponsor
- Organon and Co
Migraine Disorders
A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine
This study will evaluate the safety and efficacy of BOTOX® treatment in Korean adults with chronic migraine.
- Trial name
- NCT02147561
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 280 people
- Sponsor
- Allergan
Migraine
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound.
- Trial name
- Ubro Peds (NCT05125302)
- Testing
- Ubrogepant
- Where
- 129 sites in United States, Puerto Rico
- Volunteers
- 1,059 people
- Sponsor
- AbbVie
Migraine Disorders, Migraine
An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine
Nitric oxide (NO) is likely to be involved in the development of migraine headache. Nitric oxide synthase (NOS) is an important chemical involved in the production of NO.
- Trial name
- NCT00319137
- Testing
- GW274150
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 126 people
- Sponsor
- GlaxoSmithKline
Migraine Disorders
Chronic Migraine Epidemiology and Outcomes Study
This is a population internet-based study to characterize migraine clinical course and impact on family.
- Trial name
- NCT01648530
- Testing
- No Treatment
- Volunteers
- 16,789 people
- Sponsor
- Allergan